Drugs for Open-Angle Glaucoma
full update February 2025
The following chart has info on available glaucoma meds, including cost, select side effects, mechanism of action, and dosing frequency. For general information on glaucoma pharmacotherapy, see footnote c.
Drug |
Approximate Costa |
Select Side Effects1,3,7,10 |
Comments |
Prostaglandin analogs |
|||
Bimatoprost 0.01% Lumigan (US), Lumigan RC (Canada) |
US: $260/2.5 mL, Canada: $70/5 mL, $100/7.5 mL |
|
|
Bimatoprost0.03% (Canada) Vistitan, Zimed PF |
Vistitan: $50/5 mL Zimed PF: $60.5 mL |
||
Latanoprost0.005% Xalatan, generics |
US: $10/2.5 mL Canada: $10/2.5 mL |
||
Latanoprost 0.005% preservative-free |
US: $320/30 doses Canada: $20/30 doses |
||
Latanoprost/Netarsudil (US) Rocklatan0.005%/0.02% |
US: $350/2.5 mL |
||
Latanoprost/Timolol (Canada) Xalacom0.005%/0.5%, generics |
Canada: $10/2.5 mL |
||
Latanoprostene bunod 0.024% Vyzulta |
US: $260/2.5 mL, $520/5 mL Canada: $30/5 mL |
||
Tafluprost 0.0015%. (US) Zioptan, generics |
US: $160/30 doses |
||
Travoprost 0.003% (Canada) Izba |
Canada: $20/5 mL |
||
Travoprost 0.004%, Travatan Z, generics |
US: $80/2.5 mL, $160/5 mL Canada: $45/5 mL |
||
Travoprost/Timolol (Canada) DuoTrav PQ 0.004%/0.5%, generics |
Canada: $50/5 mL |
||
Beta-Blockers |
|||
Betaxolol 0.5% solution (US) |
US: $50/5 mL; $90/10 mL, $140/15mL |
|
|
Betaxolol 0.25% suspension Betoptic S |
US: $610/15 mL, $410/10 mL Canada: $15/5 mL |
||
Carteolol1% (US) |
US: $15/5 mL, $25/10 mL, |
||
Levobunolol (US) Betagan 0.25%, 0.5% (generic only) |
US: $20/5 mL (either strength) |
||
Timolol hemihydrate (US) Betimol 0.25%, 0.5% (generic available) |
US: $150/5 mL (Betimol 0.25%); 0.5% (generic): $110/5 mL, $210/10 ml, $290/15 mL |
||
Timolol maleate See Prostaglandins, above, for combo products Xalacom and DuoTrav PQ. |
|||
Istalol (US) 0.5%, generics |
US: $130/2.5 mL, $240/5 mL |
||
Timoptic |
US: <$5/5 mLb (0.25%), |
||
Timoptic in Ocudose (US) 0.25%. 0.5%, generics |
US: $400/60 doses (0.25%), $210/60 doses (0.5%) |
||
Timoptic XE gel forming solution 0.25%, 0.5%, generics |
US: $180/5 mL (0.25%), |
||
Timolol/Brimonidine Combigan 0.5%/0.2%, generics |
US: $100/5 mL, $200/10 mL, $330/15 mL Canada: $25/10 mL |
||
Timolol/Brinzolamide (Canada) Azarga 0.5%/1% |
Canada: $20/5 mL |
||
Timolol/Dorzolamide 0.5%/2%, Cosopt, Cosopt PF (US), generics; Cosopt Preservative-Free (Canada) |
US: $30/10 mL; $120/60 doses (preservative-free) Canada: $20/10 mL; |
||
Carbonic Anhydrase Inhibitors |
|||
Acetazolamide (oral) 125 mg tablet (US), 250 mg tablet; 500 mg extended-relase capsule (US) |
500 mg ER BID dose or 250 mg IR QID dose: US: $80/30 days Canada: $20/30 days (IR) |
Topical:
Oral:
|
|
Brinzolamide1% Azopt1%, generics (US) (See Beta-Blockers section for combo product Azarga [Canada]) |
US: $300/10 mL, $450/15 mL Canada: $20/5 mL |
||
Brinzolamide/Brimonidine Simbrinza 1%/0.2% |
US: $210/8 mL Canada: $50/10 mL |
||
Dorzolamide 2% Trusopt, generics Trusopt Preservative-Free (Canada) (See Beta-Blockers section for combo products Cosopt, Cosopt PF [US], Cosopt Preservative-Free [Canada]) |
US: $20/10 mL Canada: <$10/5 mL; $80/60 doses (preservative-free) |
||
Methazolamide (oral) |
50 mg BID dose: US: $260/30 days Canada: $40/30 days |
||
Alpha-2 Agonists |
|||
Apraclonidine 0.5% Iopidine (generics [US]) |
US: $60/5 mL; $130/10 mL Canada: $30/5 mL |
|
|
Brimonidine Alphagan 0.2% (Canada), generics Alphagan P0.1% (US only), 0.15%, generics
(See Carbonic Anhydrase Inhibitors section for combo product Simbrinza. See Beta-Blockers section for combo product Combigan) |
Alphagan 0.2% generic US ~$10 (5, 10, 15 mL) Canada: $<10/5 mL, $10/10 mL Alphagan P 0.1% generic US: $160/5 mL, $320/10 mL, $470/15 mL Alphagan P 0.15% generic US: $140/5 mL, $280/10 mL, $430/15 mL Canada: $10/5 mL, $20/10 mL |
||
Parasympathomimetics |
|||
Echothiophate Phospholine Iodide (US) |
US: $2,861.18/5 mL |
|
|
Pilocarpine generics 1%, 2%, 4% (US); Isopto-Carpine 2% (Canada) |
US: $60/15 mL (1%, 2%), $110/15 mL (4%) Canada: <$10/15 mL |
||
Rho Kinase (ROCK) Inhibitors |
|||
Netarsudil 0.02% (US) Rhopressa (See Prostaglandin analogs section for combo product Rocklatan.) |
US: $130/2.5 mL |
|
|
Abbreviations: BAK = benzalkonium chloride; IOP = intraocular pressure
- Wholesale acquisition cost (WAC) of generic, if available. US medication pricing by Elsevier, accessed February 2025.
- Other sizes may be available.
- Considerations for choosing an agent include cost, efficacy, side effects, comorbidities, patient preference, and dosing schedule.1,10 If a single medication does not produce an adequate response, switch medication classes, or add another agent.1,10 Additional efficacy is seen when agents with different mechanisms of action are used in combination.8,10 Switching within a class can be tried to address adverse effects.10 Two or three medications may be required to achieve the desired IOP reduction.10 Counsel patients to wait three to five minutes between administration of different medications.10 Combination products may improve adherence and reduce eye exposure to preservatives.1 To decrease systemic absorption, patients should be counseled to press on the bridge of the nose in the corner of the eye (i.e., nasolacrimal occlusion) during and for three to five minutes after administration, or close their eyes after administration.1,8
References
- Gedde SJ, Vinod K, Wright MM, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2021 Jan;128(1): P71-P150.
- Li T, Lindsley K, Rouse B, et al. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology. 2016 Jan;123(1): 129-40.
- Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2025. http: //www.clinicalkey.com. (Accessed February 13, 2025).
- Soltani G, Shalaby WS, Razeghinejad R. Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication. Med Gas Res. 2025 Jun 1;15(2): 220-227.
- Vaajanen A, Vapaatalo H. A Single Drop in the Eye - Effects on the Whole Body? Open Ophthalmol J. 2017 Oct 31;11: 305-314.
- Pratt NL, Ramsay EN, Kalisch Ellett LM, et al. Association between Ophthalmic Timolol and Hospitalisation for Bradycardia. J Ophthalmol. 2015;2015: 567387.
- Stoner A, Harris A, Oddone F, et al. Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand? Br J Ophthalmol. 2022 Oct;106(10): 1332-1337.
- Carey K, Hendricks BC. Eye disorders. In: Zeind CS, Carvalho MG, Cheng JWM, et al., editors. Applied Therapeutics: the Clinical Use of Drugs. 12th ed. Philadelphia, PA: Wolters Kluwer Health, 2024: 1183-1206.
- Product information for Rhopressa. Alcon Laboratories. Fort Worth, TX 76134. September 2024.
- American Optometric Association. Evidence-based clinical practice guideline. Care of the patient with primary open-angle glaucoma. First edition. Approved October 5, 2024. https: //www.aoa.org/a/19461. (Accessed February 20, 2025).
Cite this document as follows: Clinical Resource, Drugs for Open Angle Glaucoma.Pharmacist’s Letter/Pharmacy Technician’s Letter/Prescriber Insights.February 2025.[410271]